CDMO Fujifilm Diosynth Biotechnologies has launched a new strategic business unit (SBU) structure to provide tailored support biopharmaceutical customers by aligning service offerings and manufacturing capacities.
“We are confident this new structure will help to advance our customers’ goals while also creating new, exciting opportunities for growth,” said Toshi Iida, VP of Fujifilm.
The large-scale SBU is designed to meet the needs of clients who need access to high-volume cell culture production utilising multiples of 20,000 L bioreactors. These suites provide efficiencies of scale with high throughput.
The small-scale SBU provides support for clients as they navigate the regulatory matrix of Pre-Clinical, Early Clinical Phase I and II, Late Clinical Phase III, as well as those progressing to Regulatory Approval and commercial production. The production volume utilises bioreactors ranging from 200 L to 2,000 L as well as single-use manufacturing systems.
Our exceptional leadership and talented teams will play a key role in providing end-to-end support
- Lars Petersen, President of Fujifilm Diosynth Biotechnologies
“This SBU model will create long-term value for our customers and allow us to cultivate mutually beneficial partnerships and maximise efficiencies across our network,” said Lars Petersen, President of Fujifilm Diosynth Biotechnologies. “Our exceptional leadership and talented teams will play a key role in providing end-to-end support and driving continued success for our customers.”
Across these two sites, Bilenberg will be responsible for management, operations, and performance for cell culture drug substance production complemented by comprehensive drug product and finished goods services. He brings over 20 years of experience as a proven leader holding a variety of roles with expanding responsibilities in the life science and biotechnology industries.
Bilenberg joined Fujifilm Diosynth Biotechnologies in 2019 as site head for the company’s expansion project in Holly Springs. His career includes experience in finance, strategy and business planning, project management, supply chain management, procurement, facilities management, and utilities as well as IT and automation.
Kingsbury previously served as general manager and head of site at Lianhetech Seal Sands, a leading European contract manufacturer of high-quality fine chemicals for use in crop protection, pharmaceutical and performance chemical markets.
He has held several other leadership roles over the last 25 years including chief operating officer and engineering manager and has a proven track record in product development, operational improvement and value creation. Kingsbury also has global leadership experience and expertise in fast-track product development, scale-up and high quality, reliable manufacturing.
Prior to joining Fujifilm Diosynth Biotechnologies, Madsen worked at Novo Nordisk for more than 15 years in various leadership roles, most recently as global project director. Madsen is an experienced leader in commercial strategic planning, project portfolio and change management, transformation, optimisation and operations.
“This new strategic business structure with the support of the Strategy & Executive Office reinforces our commitment to innovation, superior service and quality as we partner on the development of novel lifesaving treatments,” said Petersen.
Bilenberg’s and Madsen’s appointments are effective immediately. Kingsbury will join FUJIFILM Diosynth Biotechnologies effective September 4, 2023.
